AstraZeneca said Tuesday is would acquire Fusion Pharmaceuticals for $2 billion upfront. The biotech stock nearly doubled.

The post Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover appeared first on Investor’s Business Daily.